Cd3/cd19 neg allogeneic bmt (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
65 | Primary immunodeficiency | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03330795 (ClinicalTrials.gov) | December 1, 2017 | 30/10/2017 | Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant | Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA Matched Cadaveric Donors (RTB-003) | Primary Immunodeficiency;PID | Biological: CD3/CD19 neg allogeneic BMT | National Institute of Allergy and Infectious Diseases (NIAID) | University of Pittsburgh | Recruiting | 10 Years | 45 Years | All | 8 | Phase 1;Phase 2 | United States |